• Soligenix Extends Enrollment in Phase 3 Trial of SGX301 in Cutaneous T-cell Lymphoma
  • MEI Pharma, BeiGene Will Evaluate New Combo Therapy for B-cell Cancers
  • AFM11 Clinical Program for Lymphoma and Leukemia on Hold Over Safety Concerns
  • Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces
  • FDA Committee Recommends Truxima’s Approval for 3 Non-Hodgkin’s Lymphoma Indications
  • Axicabtagene Ciloleucel Gets Japan’s Orphan Drug Designation to Treat Some Non-Hodgkin’s Lymphomas
  • Beigene’s Lymphoma Treatment Zanubrutinib Shows High Response Rates in Chinese Phase 1 Trial
  • 9 in 10 Heavily Treated CTCL Patients See Benefits with IPH4102, Phase 1 Trial Shows
  • LLS Seeks Corporate Support for Annual ‘Light The Night’ Campaign
  • Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma
  • Embracing the Insecurity
  • We Need to Talk About Survival Statistics